Ask AI
ProCE Banner Activity

New Targeted Therapies and Emerging Data in Urothelial Carcinoma

Slideset Download
Review expert guidance on integrating erdafitinib and enfortumab vedotin into management of progressive urothelial carcinoma, then get up to date on key data for sacituzumab govitecan and other promising investigational therapies.

Released: February 26, 2021

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Immunomedics

Faculty Disclosure

Primary Author

Petros Grivas, MD, PhD

Professor, Division of Hematology Oncology
Department of Medicine
Medical Director, International Program
Medical Director, Local/Regional Outreach
University of Washington
Professor, Clinical Research Division
Fred Hutchinson Cancer Center
Seattle, Washington